Items tagged with Treatment
Researchers identify rare genetic markers of drug-resistant TB (post)
Search for rare mutations in bacterial genome could lead to better diagnostics and treatments – reducing morbidity caused by the deadly disease.
A better antibiotic for tuberculosis treatment (post)
May 12, 2022 – Over the past few years of his PhD research, Harim Won has been laying the groundwork to develop a new type of antibiotic to treat tuberculosis (TB), addressing the long-standing problems of lengthy treatments and antibiotic resistance. Won is using a new approach to turn a normal protein system in the bacterial cell against itself.
Linezolid dosing as part of three-drug regimen for drug-resistant TB (post)
In February, the CDC released provisional guidance for the use of pretomanid as part of the bedaquiline, pretomanid and linezolid (BPaL) regimen to treat drug-resistant tuberculosis.
U.S. Government funded research brings shorter TB treatment regimens to New York City (post)
May 16, 2022 – We applaud the New York City Department of Health and Mental Hygiene (DoHMH) for its leadership as one of the first TB programs in the U.S. and globally to introduce a new four-month regimen for the treatment of drug-susceptible tuberculosis (TB). This new regimen represents a long-awaited breakthrough, offering a shorter alternative to the six-to-nine-month treatment in use since the 1980s. That the Department of Health and Mental Hygiene is moving forward to make this regimen available to patients will make treatment more tolerable for people living with TB. As TB survivor and activist Kate O’Brien of We Are TB and co-chair of the TB Roundtable put it, “TB treatment can be such a miserable experience, with all sorts of side effects and logistical complications. Shorter regimens offer patients welcome relief and I’m thrilled to see important government investments delivering better cures for TB.”
New TB drug combination trial – hope for shorter treatment (post)
The University of Cape Town’s Lung Institute is conducting a new trial involving BTZ-043 (benzothiazinone DprE1 blocker), a novel TB drug candidate. There are also plans to test BTZ-043 in combination with two other new TB drug candidates. If all goes well, the new drug regimen could reduce TB treatment from the current six months to four.
WHO stakeholder survey: Target Regimen Profiles for TB treatment (post)
The World Health Organization (WHO) initiated a process of updating the Target Regimen Profiles for TB treatment, initially published in 2016.
Shorter TB treatment shows promise in Nigeria (post)
-- Nigeria is one of eight countries that accounts for two-thirds of new TB cases
-- A new six-month treatment for TB is being considered for rollout nationwide
-- The WHO-recommended regimen could help combat drug resistance
Study finds TB treatment during pregnancy is safe for mum and baby (post)
Seven out of 10 pregnant women were cured of their multidrug-resistant tuberculosis and delivered healthy babies after taking a medication that had previously been considered unsafe in pregnancy, a new Curtin and Telethon Kids Institute study has found.
South Africa: Shorter, simpler DR-TB regimen expected later this year (post)
Work is underway in South Africa to amend the country’s national guidelines for drug-resistant TB to provide a shorter, six-month, all-oral regimen as a new standard of care treatment.
Being heard on all-oral therapy for resistant TB (post)
A study, published in The Lancet Infectious Diseases, compared outcomes up to 24 months after treatment initiation for patients with rifampicin-resistant TB in South Africa treated with a short, all-oral bedaquiline-containing regimen, or a short, injectable-containing regimen.
Page 64 of 108 · Total posts: 0
←First 63 64 65 Last→